Abstract
Abstract
Purpose
Many drugs are associated with the risk of QT prolongation and torsades de pointes (TdP), and different risk assessment tools (RATs) are developed to help clinicians to manage related risk. The aim of this systematic review was to summarize the evidence of different RATs for QT prolonging pharmacotherapy.
Methods
A systematic review was conducted using PubMed and Scopus databases. Studies concerning risk assessment tools for QT prolonging pharmacotherapy, including older adults, were included. Screening and selection of the studies, data extraction, and risk of bias assessment were undertaken.
Results
A total of 21 studies were included, involving different risk assessment tools. Most commonly used tools were risk scores (n = 9), computerized physician order entry systems (n = 3), and clinical decision support systems (n = 6). The tools were developed mainly for physicians and pharmacists. Risk scores included a high number of risk factors, both pharmacological and non-pharmacological, for QT prolongation and TdP. The inclusion of patients’ risk factors in computerized physician order entry and clinical decision support systems varied.
Conclusion
Most of the risk assessment tools for QT prolonging pharmacotherapy give a comprehensive overview of patient-specific risks of QT prolongation and TdP and reduce modifiable risk factors and actual events. The risk assessment tools could be better adapted to different health information systems to help in clinical decision-making. Further studies on clinical validation of risk assessment tools with randomized controlled trials are needed.
Funder
University of Helsinki including Helsinki University Central Hospital
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference52 articles.
1. Woosley RL, Heise CW, Romero KA (2018) QTdrugs List, January 2018, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Available at: www.crediblemeds.org Accessed January 24, 2018
2. Thomas SHL, Behr ER (2016) Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 81(3):420–427
3. Schwartz PJ, Woosley RL (2016) Predicting the unpredictable. Drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 67:1639–1650
4. Vandael E, Vandenberk B, Vandenberghe J et al (2017) Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 39(1):16–25
5. Laksman Z, Momciu B, Seong YW et al (2015) A detailed description and assessment of outcomes of patients with hospital recorded QTc prolongation. Am J Cardiol 115(7):907–911
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献